VIVUS: Potential for Adding More Weight in April
Favorable voting (20-2) for Qnexa (R, combination of phentermine – PHEN and topiramate – TPM) – VVUS’ anti-obesity drug, by the FDA advisory panel on Feb. 22, 2012 and approval in April (PDUFA: April 17, 2012) could finally see the launch of an efficacious drug for treating obesity. While everyone is focusing on Qnexa, there is still another drug waiting for approval in VVUS’ portfolio – Avanafil, a highly selective phosphodiesterase type 5 – PDE5 inhibitor for Erectile Dysfunction (ED). We are positive on its approval (PDUFA: April 29, 2012) based on the data and safety profile. With the risk of generics, commercial potential of Avanafil worth... The upside could be more in case of a buyout, favorable licensing deal, and positive sentiment around approval time in April… For more details, please read our report released on February 24, 2012 on VVUS, titled “Potential for Adding More Weight in April”
COMPANIES MENTIONED
VIVUS
VIVUS
